Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Skin Neoplasms 6Neoplasms 6Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Squamous Cell 4Neoplasm Metastasis 3Prostatic Neoplasms 2Lung Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Advanced Non-Small Cell Lung Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Motor Activity 1Liposarcoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2cemiplimab 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Resectable Non-small Cell Lung Cancer × cemiplimab × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡